je.st
news
Tag: patients
Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
2014-07-24 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
phase
patients
prevention
Concept Group's Shaped Vacuum Protects Patients During Cryosurgery
2014-07-22 06:00:00| Industrial Newsroom - All News for Today
Extraordinarily Thin Insulon® Thermal Barrier Protects Healthy Tissue While Cryosurgical Probe Destroys Tumors.<br /> <br /> West Berlin NJ Surgeons have long known that extreme cold temperature can destroy tumors and other unhealthy tissue. Ideally, such cold would be delivered by cryosurgical probe, to avoid the need for major invasive surgery. But how could surgeons maneuver a -321°F probe to the tumor site without freezing healthy tissue on the way in? Wrapping enough thermal insulation ...This story is related to the following:Health, Medical and Dental Supplies and EquipmentSearch for suppliers of: Thermal Barriers |
Tags: groups
concept
patients
shaped
Gilead Drug Combination Cures Hepatitis C in HIV Patients
2014-07-20 17:42:57| Biotech - Topix.net
Gilead Sciences Inc.'s Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug has the potential to limit a top cause of death in these patients.
Tags: combination
drug
patients
hiv
Late-Breaking Observational Data Show Patients with Type 2 Diabetes Taking JANUVIA (sitagliptin) and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylurea and Metformin
2014-06-14 19:01:32| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION Real-world study presented at the American Diabetes Association 74th Scientific Sessions Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients Language: English read more
New Post-Hoc Analysis Shows Patients with Type 2 Diabetes Undergoing Intensification of Insulin Therapy Experienced Less Nighttime Hypoglycemia While Being Treated with JANUVIA (sitagliptin) Compared to Placebo
2014-06-14 19:01:06| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions. Language: English read more
Sites : [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] next »